Maker of chemiluminescence immunoassay analyzers and reagents used for in-vitro diagnostic testing in hospitals and labs.
Maker of chemiluminescence immunoassay analyzers and reagents used for in-vitro diagnostic testing in hospitals and labs.
Places analyzers with hospitals and labs, then earns repeatedly from the reagents they must buy to run tests on them, a razor-and-blade model. Sales go through distributors in China and abroad, and overseas markets account for a large share.
In one line: A Chinese Abbott Diagnostics/DiaSorin for immunoassay testing.
Moat: narrow (installed base, switching costs, process know-how). Analyzer-reagent razor/razorblade model locks in labs once an instrument is placed.
Headquarters: Shenzhen, China · Founded: 1998 · Employees: 2,785
Size Shenzhen New Industries Biomedical Engineering (300832.SZ) is a China Health Care company (Medical Specialties) with a market value of $7.50B, the 312th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥61.71 on 18 Nov 2026.
Performance Over six months the shares gained 20.6%, against +31.9% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 6.6% over the last twelve months (peer median +3.2%); the operating margin is 42.7% (peer median 15.7%).
Valuation It trades at 26.9× forward earnings against a peer median of 20.9× (8th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 20.3 points above its cost of capital (5.0% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.85B | CN¥4.53B | CN¥4.53B | CN¥3.92B | CN¥3.04B |
| Revenue growth | — | 0% | +15% | +29% | — |
| Gross profit | CN¥3.52B | CN¥2.99B | CN¥3.13B | CN¥2.75B | CN¥2.06B |
| EBITDA | n/a | CN¥1.99B | CN¥2.15B | CN¥1.92B | CN¥1.46B |
| Net income | CN¥1.81B | CN¥1.62B | CN¥1.83B | CN¥1.65B | CN¥1.33B |
| Free cash flow | CN¥1.74B | CN¥1.24B | CN¥1.01B | CN¥1.18B | CN¥635M |
| Capital expenditure | CN¥322M | CN¥311M | CN¥439M | CN¥322M | CN¥403M |
| Total debt | CN¥2.63M | CN¥3.68M | CN¥4.10M | CN¥5.18M | CN¥18.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shenzhen New Industries Biomedical Engineering 300832.SZ | $7.50B | +21% | +7% | 43% | 26.9× | 2.9% |
| Abbott Laboratories ABT | $181B | +18% | +10% | 14% | 17.9× | 16.5% |
| DiaSorin DIA.MI | $4.81B | +24% | -3% | 24% | 20.5× | 4.1% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | $33.6B | +15% | +5% | 28% | 27.3× | 1.0% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 19.9× | 1.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300832.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.7% | +8.5% | 6th highest of 21 |
| 6-month return | +20.6% | +31.9% | 4th lowest of 21 |
| Distance from 52-week high | -8.1% | -6.8% | 9th lowest of 21 |
| Revenue growth (TTM) | +6.6% | +3.2% | 10th highest of 21 |
| Operating margin | 42.7% | 15.7% | highest of 21 |
| Forward P/E | 26.9× | 20.9× | 8th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 2.9% | 10.9% | 2nd least demanding of 20 |
| Growth delivered (Del g) | +15.7% | +9.3% | 6th highest of 20 |
| Hurdle (Req g minus delivered) | -12.8 pp | +2.0 pp | 5th least demanding of 20 |
| ROIC minus cost of capital | +20.3 pp | +2.8 pp | 2nd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.50B | +21% | +7% | 43% | 26.9× | 2.9% | +15.7% |
| Getinge GETI-B.ST | Sweden | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% | +3.2% |
| Bausch + Lomb BLCO.TO | Canada | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% | +10.0% |
| Asahi Intecc 7747.T | Japan | $7.09B | +24% | +23% | 32% | 29.7× | 15.1% | +18.8% |
| Sysmex 6869.T | Japan | $8.06B | +58% | +8% | 13% | 32.0× | 4.4% | +10.4% |
| Shimadzu 7701.T | Japan | $8.14B | +24% | +8% | 14% | 21.0× | 8.3% | +7.3% |
| Ypsomed YPSN.SW | Switzerland | $6.83B | +27% | -13% | 30% | 31.7× | n/a | n/a |
| ConvaTec CTEC.L | United Kingdom | $6.78B | +37% | +2% | 16% | 17.7× | 17.2% | +4.6% |
| Cochlear COH.AX | Australia | $6.72B | +58% | -1% | 13% | 29.1× | 23.9% | +9.3% |
| Lantheus LNTH | United States | $6.67B | +6% | +2% | 19% | 15.5× | 0.4% | +35.3% |
| Teleflex TFX | United States | $6.58B | +23% | -29% | 12% | 16.7× | 16.5% | -4.7% |
| APT Medical 688617.SS | China | $6.06B | +23% | +28% | 37% | 38.6× | 9.0% | +40.1% |
| Globus Medical GMED | United States | $9.34B | -16% | +13% | 23% | 13.7× | 4.6% | +30.1% |
| Bruker BRKR | United States | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% | +11.6% |
| Insulet PODD | United States | $9.71B | -11% | +26% | 18% | 18.6× | 10.6% | +24.5% |
| Haemonetics HAE | United States | $5.59B | +106% | +4% | 19% | 20.7× | 10.9% | +8.9% |
| Bio-Rad Laboratories BIO | United States | $10.1B | +29% | +1% | 9% | 34.6× | 26.0% | +0.3% |
| Qiagen QGEN | United States | $10.2B | +41% | +2% | 25% | 19.5× | 8.6% | +2.2% |
| Demant A/S DEMANT.CO | Denmark | $10.4B | +39% | +10% | 18% | 23.2× | 5.8% | +9.8% |
| Avantor AVTR | United States | $10.4B | +95% | +1% | 8% | 17.5× | 16.4% | +0.5% |
| LivaNova LIVN | United States | $5.21B | +28% | +12% | 15% | 20.9× | 14.2% | +8.2% |